Press Releases

• Oct 9, 2017 AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors
• Oct 4, 2017 AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board
• Aug 7, 2017 AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
• Jul 25, 2017 AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101
• Jul 17, 2017 AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
• Jun 5, 2017 AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
• May 1, 2017 AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
• Mar 22, 2017 AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
• Dec 15, 2016 AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
• Sep 22, 2016 AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea